Cladribine (Leustatin)

General information

Class/mechanism: Purine analog; mimics the nucleoside adenosine, inhibiting adenosine deaminase, which interferes with DNA synthesis and repair.
Route: IV, SC
Extravasation: irritant or neutral, depending on reference

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Diseases for which it is established (work in progress)

• Mantle cell lymphoma

Diseases for which it is used

• Acute myeloid leukemia
• B-cell lymphoma of mucosa-associated lymphoid tissue
• Chronic lymphocytic leukemia
• Follicular lymphoma
• Hairy cell leukemia
• Hypereosinophilic syndrome
• Langerhans cell histiocytosis
• Marginal zone lymphoma
• Systemic mastocytosis
• Waldenström macroglobulinemia

Patient drug information

• Cladribine package insert
• Cladribine (Leustatin) patient drug information (Chemocare)
• Cladribine (Leustatin) patient drug information (UpToDate)

History of changes in FDA indication

• 1993-02-26: Initial FDA approval for treatment of active hairy cell leukemia. (Based on Saven et al. 1998)

Also known as

• Generic names: 2-chlorodeoxyadenosine, 2-CdA
• Brand names: Leustatin, Litak, Movectro